Detalles de la búsqueda
1.
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 73(4): 70, 2024 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38430375
2.
Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors.
J Clin Pharmacol
; 63(7): 817-829, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36852723
3.
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Clin Cancer Res
; 29(11): 2066-2074, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36806911
4.
Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study.
Jpn J Clin Oncol
; 41(5): 718-22, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21393255
5.
Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy.
CPT Pharmacometrics Syst Pharmacol
; 10(3): 230-240, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33465293
6.
Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma.
Oncoimmunology
; 10(1): 1898104, 2021 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33796405
7.
Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy.
Clin Cancer Res
; 26(1): 61-70, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31801732
8.
An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.
Cancer Chemother Pharmacol
; 82(4): 685-694, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30073583
9.
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Clin Lung Cancer
; 18(5): 589-593, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28690011
10.
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
J Clin Oncol
; 35(31): 3591-3600, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28892431
11.
Response to 'Dai W et al. Am J Cancer Res 2015;5(10):3270-3275' from the makers of nintedanib.
Am J Cancer Res
; 6(7): 1547-8, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27508096
12.
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
J Clin Oncol
; 27(27): 4454-61, 2009 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19687335
Resultados
1 -
12
de 12
1
Próxima >
>>